Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc (NASDAQ:AMRN) is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular disease. The company’s primary product is icosapent ethyl, an omega-3 fatty acid formulation derived from eicosapentaenoic acid (EPA).

In the United States, icosapent ethyl is marketed as Vascepa and is approved as an adjunct to diet for certain patients with elevated triglyceride levels. It is also approved to reduce the risk of cardiovascular events, such as heart attack and stroke, in specified high-risk adult patients. In Europe, the product is marketed under the name Vazkepa for eligible patients with elevated cardiovascular risk.

Amarin was founded in 1993 and has historically concentrated on cardiovascular-focused drug development and commercialization. The company has pursued regulatory approvals and commercial operations in the United States and selected international markets, including countries in Europe. Its business remains centered on expanding access to and use of icosapent ethyl as part of cardiovascular risk management.

Key Stats

• Today's Range: $11.95 to $12.20
• 50-Day Range: $11.99 to $14.41
• 52-Week Range: $11.83 to $20.90
• Volume: 44,853 shs
• Average Volume: 57,593 shs
• Market Capitalization: $254.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Hold

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 30% of companies evaluated by MarketBeat, and ranked 775th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Amarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Amarin is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amarin has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Amarin are expected to grow in the coming year, from ($0.85) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -12.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -12.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.61% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 10.54, which indicates bearish sentiment.

Change versus previous month

Short interest in Amarin has recently increased by 0.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.10

News Sentiment

Amarin has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Amarin this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.21% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

22.25% of the stock of Amarin is held by institutions.

Company Calendar

• Last Earnings: 2/25/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 80
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Amarin: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +8.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.80 million
• Net Margins: -14.56%
• Pretax Margin: -13.73%
• Return on Equity: -0.20%
• Return on Assets: -0.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.67
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $213.65 million
• Price / Sales: 1.19
• Cash Flow: $0.36 per share
• Price / Cash Flow: 33.33
• Book Value: $22.07 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 21,120,000
• Free Float: 20,234,000
• Market Cap: $254.07 million
• Optionable: Optionable
• Beta: 0.76